Papuloerythroderma heralding recurrence of an aggressive T-cell Leukemia

Al-musalhi, 2016, Small Cell Variant of T-Cell prolymphocytic leukemia with acquired palmoplantar keratoderma and cutaneous infiltration, Oman Med. J., 31, 73, 10.5001/omj.2016.14 César, 2016, Erythroderma . a clinical and etiological study of 103 patients, J. Dermatol. Case Rep., 1, 1 Chandran, 2016, Survival trends in T cell prolymphocytic leukemia: a SEER database analysis, Leuk. Lymphoma., 57, 942, 10.3109/10428194.2015.1076932 Collignon, 2017, Prolymphocytic leukemia: new insights in diagnosis and in treatment, Curr. Oncol. Rep., 19, 10.1007/s11912-017-0581-x Dearden, 2001, High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H, Blood, 98, 1721, 10.1182/blood.V98.6.1721 Dearden, 2012, How I treat prolymphocytic leukemia, Blood, 120, 538, 10.1182/blood-2012-01-380139 Dholaria, 2018, Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: a single-center experience, Leuk. Res., 67, 1, 10.1016/j.leukres.2018.01.009 Gandhi, 2008, Phase I trial of nelarabine in indolent leukemias, J. Clin. Oncol., 26, 1098, 10.1200/JCO.2007.14.1986 Graham, 2013, T-cell prolymphocytic leukemia, Proc (Bayl Univ Med Cent), 26, 19, 10.1080/08998280.2013.11928902 Guillaume, 2015, Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC), Eur. J. Haematol., 94, 265, 10.1111/ejh.12430 Herbaux, 2015, Bendamustine is effective in T-Cell prolymphocytic leukaemia, Br. J. Haematol., 168, 916, 10.1111/bjh.13175 Herling, 2008, High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia, Blood, 111, 328, 10.1182/blood-2007-07-101519 Ho, 1999, Pentostatin in T-cell malignancies - A phase II trial of the EORTC, Ann. Oncol., 10, 1493, 10.1023/A:1008377724139 Hopfinger, 2013, Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia, Cancer, 119, 2258, 10.1002/cncr.27972 Jain, 2017, Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL), Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 28, 1554, 10.1093/annonc/mdx163 Laribi, 2017, Advances in the understanding and management of T-cell prolymphocytic leukemia, Oncotarget, 8, 104664, 10.18632/oncotarget.22272 Mallett, 1995, Cutaneous infiltration in T-cell prolymphocytic leukaemia, Br. J. Dermatol., 132, 263, 10.1111/j.1365-2133.1995.tb05023.x Matutes, 1991, Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia, Blood, 78, 3269, 10.1182/blood.V78.12.3269.3269 Mercieca, 1994, The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype, J. Clin. Oncol., 12, 2588, 10.1200/JCO.1994.12.12.2588 Nakagawa, 2018, Papuloerythroderma-like cutaneous involvement of a CD62L− subclone of T-cell prolymphocytic leukemia, J. Dermatol., 46, 65, 10.1111/1346-8138.14702 Sud, 2017, T-cell Prolymphocytic Leukemia, Hematol. Oncol. Clin. North Am., 31, 273, 10.1016/j.hoc.2016.11.010 Vivekanandarajah, 2013, T-cell prolymphocytic leukaemia (T-PLL): A rare disease with a grave prognosis, BMJ Case Rep., 1 Watanabe, 2014, Alemtuzumab therapy for leukemic CTCL: Diffuse erythema as a positive predictor of complete remission, JAMA Dermatol., 150, 776, 10.1001/jamadermatol.2013.10099